In search of mechanisms to explain the unquestionable benefit derived from sodium-glucose cotransporter-2 (SGLT-2) inhibitors use in heart failure patients

References

• Sidney S, Quesenberry CP, Jaffe MG, et al. Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol. 2016;1(5):594–599.
   PubMed Web of Science ®Google Scholar
• Shah NS, Lloyd‐Jones DM, O’Flaherty M, et al. Trends in cardiometabolic mortality in the United States, 1999–2017. JAMA. 2019;322:780–782c.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Muntner P, Alonso A, et al. American heart association council on epidemiology and prevention statistics committee and stroke statistics subcommittee. heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019Mar5;139(10):e56–e528. Erratum in: Circulation. 2020 Jan 14;141(2):e33.PMID: 30700139.
   PubMed Web of Science ®Google Scholar
• Maruthur NM, Wang NY, Appel LJ. Lifestyle interventions reduce coronary heart disease risk: results from the PREMIER trial. Circulation. 2009Apr21;119(15):2026–2031. Epub 2009 Apr 6. PMID: 19349322; PMCID: PMC2995494.
   PubMed Web of Science ®Google Scholar
• Bots SH, Onland-Moret NC, Jancev M, et al. Statins are associated with a large reduction in all-cause mortality in women from a cardiac outpatient population. Open Heart. 2022Apr9;1:e001900. PMID: 35444049; PMCID: PMC9021779. 10.1136/openhrt-2021-001900
   PubMed Web of Science ®Google Scholar
• Nowbar AN, Gitto M, Howard JP, et al. Mortality from ischemic heart disease. Circ Cardiovasc Qual Outcomes. 2019;12:e005375.
   PubMed Web of Science ®Google Scholar
• Glynn P, Lloyd‐Jones DM, Feinstein MJ, et al. Disparities in cardiovascular mortality related to heart failure in the United States. J Am Coll Cardiol. 2019;73:2354–2355.
   PubMed Web of Science ®Google Scholar
• Sidney S, Go AS, Jaffe MG, et al. Association between aging of the US Population and heart disease mortality from 2011 to 2017. JAMA Cardiol. 2019;4:1280–1286.
   PubMed Web of Science ®Google Scholar
• Velagaleti RS, Vasan RS. Heart failure in the twenty-first century: is it a coronary artery disease or hypertension problem? Cardiol Clin. 2007Nov;25(4):487–495. PMID: 18063154; PMCID: PMC2350191.
   PubMed Web of Science ®Google Scholar
• Ebong IA, Goff DC Jr, Rodriguez CJ, et al. Mechanisms of heart failure in obesity. Obes Res Clin Pract. 2014 Nov-Dec 6;8(6):e540–8. Epub 2014 Jan 6. PMID: 25434909; PMCID: PMC4250935.
   PubMed Web of Science ®Google Scholar
• Dunlay SM, Givertz MM, Aguilar D, et al. American heart association heart failure and transplantation committee of the council on clinical cardiology; council on cardiovascular and stroke nursing; and the heart failure society of America. type 2 diabetes mellitus and heart failure: a scientific statement from the American heart association and the heart failure society of America: this statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019Aug13;140(7):e294–e324. Epub 2019 Jun 6. Erratum in: Circulation. 2019 Sep 17;140(12):e692.PMID: 31167558.
   PubMed Web of Science ®Google Scholar
• Lechat P. The evolution of heart failure management over recent decades: from CONSENSUS to CIBIS. Eur Heart J Suppl. 2006;8(supplC):C5–C12.
   Web of Science ®Google Scholar
• Truby LK, Rogers JG. Advanced heart failure: epidemiology, diagnosis, and therapeutic approaches. JACC Heart Fail. 2020Jul8;7:523–536. Epub 2020 Jun 10. PMID: 32535126. 10.1016/j.jchf.2020.01.014
   PubMed Web of Science ®Google Scholar
• Docherty KF, Vaduganathan M, Solomon SD, et al. Sacubitril/Valsartan: neprilysin Inhibition 5 years after PARADIGM-HF. JACC Heart Fail. 2020Oct8;10:800–810. Erratum in: JACC Heart Fail. 2020 Dec;8(12):1057.PMID: 33004114; PMCID: PMC8837825. 10.1016/j.jchf.2020.06.020
   PubMed Web of Science ®Google Scholar
• Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia. 2018;61(10):2079–2086.
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017Feb;60(2):215–225. Epub 2016 Nov 22. PMID: 27878313; PMCID: PMC5884445.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017Jan;28(1):368–375. Epub 2016 Aug 18. PMID: 27539604; PMCID: PMC5198289.
   PubMed Web of Science ®Google Scholar
• TA M, Metra M, Adamo M, et al. ESC Scientific document group. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021Sep21;42(36):3599–3726. Erratum in: Eur Heart J. 2021 Oct 14;: PMID: 34447992.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. AHA/ACC/HFSA guideline for the management of heart failure: executive summary: a report of the American college of cardiology/American heart association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022May3;79(17):1757–1780. Epub 2022 Apr 1. PMID: 35379504.
   PubMed Web of Science ®Google Scholar
• Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021Feb11;42(6):681–683. PMID: 33447845; PMCID: PMC7878007.
   PubMed Web of Science ®Google Scholar
• Komajda M, Böhm M, Borer JS, et al. Incremental benefit of drug therapies for chronic heart failure with reduced ejection fraction: a network meta-analysis. Eur J Heart Fail. 2018;20:1315–1322.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Docherty KF, Claggett BL, et al. inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomized controlled trials. Lancet. 2022Sep3;400(10354):757–767. Epub 2022 Aug 27. PMID: 36041474.
   PubMed Web of Science ®Google Scholar
• Vaduganathan M, Claggett BL, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials. Lancet. 2020;396:121–128.
   PubMed Web of Science ®Google Scholar
• Verma S, JJV M, Cherney DZI. The metabolodiuretic promise of sodium-dependent glucose cotransporter 2 inhibition: the search for the sweet spot in heart failure. JAMA Cardiol. 2017;2:939–940.
   PubMed Web of Science ®Google Scholar
• Hallow KM, Helmlinger G, Greasley PJ, et al. Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis. Diabetes Obes Metab. 2018;20:479–487.
   PubMed Web of Science ®Google Scholar
• Kapelios CJ, Malliaras K, Kaldara E, et al. Loop diuretics for chronic heart failure: a foe in disguise of a friend? Eur Heart J Cardiovasc Pharmacother. 2018;4(1):54–63.
   PubMed Web of Science ®Google Scholar
• Lam CSP, Chandramouli C, Ahooja V, et al. Inhibitors in heart failure: current management, unmet needs, and therapeutic prospects. J Am Heart Assoc. 2019 Oct 15;8(20):e013389. Epub 2019 Oct 12. PMID: 31607208; PMCID: PMC6818035.
   PubMed Web of Science ®Google Scholar
• Omar M, Jensen J, Burkhoff D, et al. Effect of empagliflozin on blood volume redistribution in patients with chronic heart failure and reduced ejection fraction: an analysis from the empire HF randomized clinical. Trial. Circ Heart Fail. 2022Mar;15(3):e009156. Epub 2021 Nov 8. PMID: 34743533.
   PubMed Web of Science ®Google Scholar
• Fudim M, Kaye DM, Borlaug BA, et al. Venous tone and stressed blood volume in heart failure: JACC review topic of the week. J Am Coll Cardiol. 2022May10;79(18):1858–1869. PMID: 35512865; PMCID: PMC9097251.
   PubMed Web of Science ®Google Scholar
• Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011;4:669–675.
   PubMed Web of Science ®Google Scholar
• Fudim M, Patel MR, Boortz-Marx R, et al. Splanchnic nerve block mediated changes in stressed blood volume in heart failure. JACC Heart Fail. 2021Apr9;4:293–300. Epub 2021 Mar 10. PMID: 33714749. 10.1016/j.jchf.2020.12.006
   PubMed Web of Science ®Google Scholar
• AC GUYTON. Determination of cardiac output by equating venous return curves with cardiac response curves. Physiol Rev. 1955Jan;35(1):123–129. PMID: 14356924.
   PubMed Web of Science ®Google Scholar
• Funk DJ, Jacobsohn E, Kumar A. The role of venous return in critical illness and shock-part I: physiology. Crit Care Med. 2013Jan;41(1):255–262. PMID: 23269130.
   PubMed Web of Science ®Google Scholar
• Sj M, Brierley L, TM C, et al. Scottish diabetes research network epidemiology group. The effect of dapagliflozin on glycaemic control and other cardiovascular disease risk factors in type 2 diabetes mellitus: a real-world observational study. Diabetologia. 2019Apr;62(4):621–632. Epub 2019 Jan 10. PMID: 30631892.
   PubMed Web of Science ®Google Scholar
• Bjornstad P, Laffel L, Tamborlane WV, et al. Acute effect of empagliflozin on fractional excretion of sodium and eGFR in YOUTH WITH TYPE 2 diabetes. Diabetes Care. 2018Aug;41(8):e129–e130. Epub 2018 Jun 25. PMID: 29941496; PMCID: PMC6054503.
   PubMed Web of Science ®Google Scholar
• Thomson SC, Rieg T, Miracle C, et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul. Integr Comp Physiol. 2012Jan1;302(1):R75–83. Epub 2011 Sep 21. PMID: 21940401; PMCID: PMC3349378.
   PubMed Web of Science ®Google Scholar
• JJV M, Packer M. How should we sequence the treatments for heart failure and a reduced ejection fraction?: a redefinition of evidence-based medicine. Circulation. 2021Mar2;143(9):875–877. Epub 2020 Dec 30. PMID: 33378214.
   PubMed Web of Science ®Google Scholar